Biotechnology - Licensing, Biotechnology

Filter

Current filters:

LicensingBiotechnology

Popular Filters

1 to 25 of 426 results

Signum Dermalogix licenses SIG990 to Dermata Therapeutics for rosacea

Signum Dermalogix licenses SIG990 to Dermata Therapeutics for rosacea

25-03-2015

Dermatology biotech company Signum Dermalogix has entered into an agreement with Dermata Therapeutics…

BiotechnologyDermatologicalsLicensingResearchSignum Dermalogix

Bristol-Myers acquires rights to Novo Nordisk program focused on autoimmune diseases

Bristol-Myers acquires rights to Novo Nordisk program focused on autoimmune diseases

24-03-2015

US pharma major Bristol-Myers Squibb has agreed to acquire from Danish diabetes care giant Novo Nordisk…

BiotechnologyBristol-Myers SquibbGlobalImmunologicalsLicensingNovo Nordisk

Takeda in-licenses ImmunoGen’s antibody-drug conjugate technology

Takeda in-licenses ImmunoGen’s antibody-drug conjugate technology

23-03-2015

US biotech firm ImmunoGen (Nasdaq: IMGN) saw its shares leap 17% to $8.74 in early morning trading on…

BiotechnologyImmunoGenLicensingOncologyTakeda Pharmaceutical

Pfenex gets early HSR clearance for collaboration with Hospira

23-03-2015

The US Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino…

BiosimilarsBiotechnologyGenentechHospiraLicensingLucentisOphthalmicsPF582PfenexRegulationRocheUSA

Confluence Pharma inks deal with AOP Orphan for Fragile X syndrome drug

23-03-2015

Privately-held USA-based Confluence Pharmaceuticals and Austria’s AOP Orphan Pharmaceuticals have signed…

AOP Orphan PharmaceuticalsBiotechnologyConfluence PharmaceuticalsEuropeLicensingMarkets & MarketingRare diseases

Intarcia and Numab link up to develop once-yearly therapies in diabetes and other indications

20-03-2015

Privately-held US biotech firm Intarcia Therapeutics and Swiss firm Numab have announced a strategic…

BiotechnologyDiabetesImmunologicalsIntarcia TherapeuticsITCA 650LicensingMetabolicsNumab

AbbVie and C2N ink global license deal for Alzheimer's disease therapy

AbbVie and C2N ink global license deal for Alzheimer's disease therapy

19-03-2015

US drugmaker AbbVie has entered into an exclusive worldwide license agreement with C2N Diagnostics, a…

AbbVieBiotechnologyC2N DiagnosticsGlobalLicensingNeurological

NantWorks and Sorrento enter second collaboration on novel anti-cancer immunotherapies

NantWorks and Sorrento enter second collaboration on novel anti-cancer immunotherapies

17-03-2015

Privately-held NantWorks and Sorrento Therapeutics have entered into a second global collaboration, this…

BiotechnologyLicensingNantworksOncologyResearchSorrento Therapeutics

Genmab will not exercise co-development right for HuMax-TAC-ADC

16-03-2015

Danish drugmaker Genmab has chosen not to exercise the co-development right for HuMax-TAC-ADC under its…

ADC TherapeuticsBiotechnologyGenmabHuMax-TACLicensingOncology

Epizyme regains rights to cancer program from Eisai

Epizyme regains rights to cancer program from Eisai

13-03-2015

US clinical stage biotech firm Epizyme’s) shares rose 14.7% to $25.45 by close of trading on Thursday,…

BiotechnologyEisaiEpizymeEPZ-6438LicensingOncology

MultiCell and Oxis Biotech sign antibody-drug conjugate collaboration

MultiCell and Oxis Biotech sign antibody-drug conjugate collaboration

13-03-2015

MultiCell Immunotherapeutics (MCIT), a majority owned subsidiary of MultiCell Technologies, has signed…

BiotechnologyLicensingMultiCell ImmunotherapeuticsMultiCell TechnologiesOncologyOxis BiotechResearch

EMD Serono and Opexa amend deal on MS drug candidate Tcelna

EMD Serono and Opexa amend deal on MS drug candidate Tcelna

09-03-2015

EMD Serono, the US biopharmaceutical division of Germany’s Merck KGaA has amended its agreement with…

BiotechnologyEMD SeronoFinancialLicensingMerck KGaANeurologicalOpexa TherapeuticsResearchTcelna

Arrowhead acquires Novartis' RNAi R&D portfolio

Arrowhead acquires Novartis' RNAi R&D portfolio

07-03-2015

USA-based nano-medicine developer Arrowhead Research Corp revealed on Thursday that it has acquired Swiss…

Arrowhead ResearchArrowhead Research CorpBiotechnologyLicensingNovartis

Spero Therapeutics gains rights to novel anti-infectives developed at HZI

Spero Therapeutics gains rights to novel anti-infectives developed at HZI

06-03-2015

Ascenion, the technology transfer partner of Germany’s Helmholtz Center for Infection Research (HZI),…

Antibiotics and Infectious diseasesBiotechnologyLicensingResearchSpero Therapeutics

Norgine partners with Navidea for Lymphoseek marketing in Europe

05-03-2015

Netherlands-headquartered independent drugmaker Norgine says that its affiliate, SpePharm AG, has entered…

BiotechnologyEuropeLicensingLymphoseekNavidea BiopharmaceuticalsNorgineOncology

arGEN-X exercises option on ARGX-115 to target immune checkpoint in cancer

arGEN-X exercises option on ARGX-115 to target immune checkpoint in cancer

04-03-2015

Clinical-stage biopharma company arGEN-X has exercised its option to exclusively license preclinical…

arGEN-XBelgiumBiotechnologyLicensingOncology

Bavarian Nordic set to earn $975 million in Prostvac deal

Bavarian Nordic set to earn $975 million in Prostvac deal

04-03-2015

Danish biotech firm Bavarian Nordic has granted US pharma major Bristol-Myers Squibb an exclusive option…

Bavarian NordicBiotechnologyBristol-Myers SquibbLicensingOncologyProstvacVaccinesYervoy

Islet Sciences gains certain rights for Phase II SGLT2 inhibitor remogliflozin

Islet Sciences gains certain rights for Phase II SGLT2 inhibitor remogliflozin

03-03-2015

US biotech firm Islet Sciences has entered into a license agreement with Brighthaven Ventures (BHV) for…

BiotechnologyBrighthaven VenturesDiabetesIslet SciencesLicensingNephrology and Hepatologyremogliflozin

Amgen licenses AMG 714 to start-up Celimmune

Amgen licenses AMG 714 to start-up Celimmune

02-03-2015

USA-based biotech company Amgen has licensed a Phase II-stage anti-IL-15 monoclonal antibody, AMG 714,…

AmgenBiotechnologyGastro-intestinalsImmunologicalsLicensingUSA

Amarin in deal with Eddingpharm to commercialize Vascepa in China

Amarin in deal with Eddingpharm to commercialize Vascepa in China

28-02-2015

US biotech firm Amarin has entered into an exclusive agreement for Chinese drugmaker Eddingpharm to develop…

AmarinBiotechnologyCardio-vascularChinaEddingpharmLicensingVascepa

AstraZeneca inks deal with Orca for autoimmune disease drugs

AstraZeneca inks deal with Orca for autoimmune disease drugs

25-02-2015

Anglo-Swedish pharma major AstraZeneca and Orca Pharmaceuticals, a UK based biopharmaceutical company,…

AstraZenecaBiotechnologyImmunologicalsInflammatory diseasesLicensingOrca PharmaceuticalsRespiratory and PulmonaryUK

Genmab inks DuoBody deal with BioNovion in the field of immuno-oncology

19-02-2015

Danish biotech company Genmab has entered into a co-development and commercialization agreement with…

BioNovionBiotechnologyDuoBodyGenmabImmunologicalsLicensingOncologyResearch

Ono signs deal with Dako for Opdivo companion diagnostic test

Ono signs deal with Dako for Opdivo companion diagnostic test

16-02-2015

Japanese pharma company Ono Pharmaceutical and Danish diagnostic provider Dako have signed a new partnership…

BiotechnologyDakoJapanLicensingOncologyOno PharmaceuticalOpdivo

TiGenix and Lonza sign agreement for the manufacture of Crohn’s disease treatment

TiGenix and Lonza sign agreement for the manufacture of Crohn’s disease treatment

12-02-2015

Swiss CMO Lonza and Belgian cell therapy firm TiGenix have agreed that Lonza will manufacture material…

BiotechnologyGastro-intestinalsLicensingLonzaTiGenixUSA

1 to 25 of 426 results

Back to top